Transforming cancer testing through clinical insight
Delivering answers through purpose-driven innovation
Developed by Mayo Clinic experts, our oncology testing is designed to improve workflow and deliver trusted answers that reduce uncertainty and support confident treatment decisions. Our suite of testing is aligned with World Health Organization and National Comprehensive Cancer Network guidelines through the entire testing lifecycle: diagnosis, prognosis, therapy selection, and monitoring.
At Mayo Clinic Laboratories, we innovate with a purpose, incorporating cutting-edge technologies like next-generation sequencing (NGS), methylation, cytogenetics, and RNA sequencing that have a proven impact on patient outcomes.
The right test at the right time
Mayo Clinic Laboratories takes the lead in designing and optimizing testing based on specific disease states. Our comprehensive oncology test menu includes evaluations that cover the cancer spectrum, including breast, endocrine, gastrointestinal, genitourinary, gynecological, head and neck, lung, neurological, sarcoma, and skin.
Mayo’s oncology portfolio spans somatic and germline genomics, cytogenetics, immunophenotyping, protein expression, and disease monitoring, enabling detailed information to aid diagnosis and prognosis and to guide patient care across the full spectrum of malignancies. By offering testing for both acquired and inherited cancers in one place, Mayo Clinic Laboratories is the singular resource for all cancer testing.
Featuring esoteric evaluations for complex diseases, our full-spectrum test menu enables end-to-end testing in one laboratory setting. Because we are part of a clinical practice and the reference lab for Mayo Clinic, your tests are run right alongside tests from Mayo Clinic patients.
This integration enables:
- Development of testing that decreases overutilization by encouraging stewardship of cytogenetics and somatic and germline testing.
- Reporting designed by leaders in their field.
- 24/7 access to laboratory specialists who provide expertise, consultative support, and clarity on results interpretation.
Breast and gynecological cancer
Our broad menu of somatic and germline testing for breast and gynecological cancer incorporates a variety of modalities for a breadth and depth of testing for women’s cancers.
Colorectal and gastrointestinal cancer
Utilizing advanced technologies, including NGS and cell-free DNA analysis, our colorectal and gastrointestinal cancer testing is focused, cost-effective, and clinically backed.
Hereditary cancer
Our germline test menu for hereditary cancer complements our somatic offerings, allowing for streamlined cancer evaluations in one laboratory.
Lung cancer
We innovate at the speed of medical advancement and offer comprehensive options for diagnostic, prognostic, and predictive lung cancer testing.
Melanoma
Our melanoma testing uses next-generation sequencing to identify variants in 17 genes associated with diagnosis, prognosis, and treatment guidance.
Neuro-oncology
Backed by a clinical practice recognized for excellence in treating patients who have cancer, our advanced testing for neuro-oncology cancer combines molecular and cytogenetic analysis to complement morphological and histological assessment.
Sarcoma
By including gene mutations and fusions described in more than 100 types of soft tissue, bone, and other mesenchymal tumors, our sarcoma panels improve diagnostic accuracy and overall patient management.
Highlights
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss updates on the Protecting Access to Medicare Act (PAMA) and other policy changes affecting clinical diagnostics. Later, Dr. Pritt welcomes Ann Moyer, M.D., Ph.D., a molecular genetic pathologist at Mayo Clinic and chair of the hereditary genetics practice, to explore how precision therapeutics are improving cancer treatments.
Autoimmune neurology testing has evolved beyond limited paraneoplastic evaluations to phenotype-specific panels that identify clinically relevant antibodies. This phenotype-specific approach significantly improves diagnostic accuracy, reduces false positives, and helps guide faster, more personalized treatment for complex neurological diseases.
Learn more about Mayo Clinic Laboratories’ new genome-wide methylation array from the Mayo Clinic neuro-oncology testing experts who worked alongside the National Institutes of Health to develop the innovative, first-in-class assay.
New wtRNA-seq test detects fusions in 1,445 genes with high accuracy, improving cancer diagnosis, treatment decisions, and clinical trial eligibility.
Research improves the diagnosis of rare Birt-Hogg-Dubé syndrome, closing genetic testing gaps, guiding care, and earning recognition as a top paper.
This microlearning provides a practical, structured approach to evaluating specimens for molecular testing using real examples and criteria drawn from laboratory practice to support confident, consistent decision-making.
Learn more about how Mayo Clinic Laboratories approach to whole transcriptome RNA sequencing provides the most comprehensive detection of gene fusions in solid tumors through use of next-generation sequencing to identify fusions in 1,445 genes.
LiquidHALLMARK combines DNA and RNA for more accurate cancer profiling, helping patients access lifesaving therapies.
Join us for a webinar exploring how LiquidHALLMARK®, a cutting-edge liquid biopsy test, is transforming cancer care.
Linda Hasadsri, M.D., Ph.D., and Huong Cabral, M.S., CGC, explain how Mayo Clinic Laboratories' expanded test panel captures rarer as well as more common genetic causes of hereditary pancreatitis. That information is key to managing patients' enhanced risk for pancreatic cancer.
Mayo Clinic Laboratories’ newly expanded Hereditary Pancreatitis Gene Panel is transforming how clinicians diagnose and manage a complex, often elusive disease. Developed through close collaboration between lab scientists, genetic counselors, and clinicians, the test uses a whole exome sequencing backbone to analyze nine carefully selected genes with strong clinical relevance. This focused approach avoids ambiguous results while empowering early diagnosis, cancer risk assessment, and family testing. Built on a whole exome backbone with reflex capabilities, the panel represents a major step forward in precision medicine — offering clarity for patients and providers, and a platform for future genomic innovation.
PACE/State of FL - The role of cytology specimens in molecular genetic testing, emphasizing their effectiveness in identifying biomarkers critical for targeted therapies in patients with cancer.
Explore the advantages of Mayo Clinic Laboratories’ oncology testing.
Learn more about our complete menu of oncology testing. Schedule a time to discuss with one of our clinical specialists.